Autologous GvHD, auto-GvHD or 'auto-aggression syndrome' was first described by Hood et al. 1 in a patient who received autologous hematopoietic cell transplant (HCT) and developed a complex of clinical, laboratory and histologic features similar to those occurring in acute GvHD after an allogeneic HCT. GvHD, a major complication after allogeneic HCT, is attributed to donor T-cell recognition of the disparate recipient histocompatibility Ags as 'foreign', which results in the production of inflammatory cytokines and cytotoxic effector cells. 2 The existence of autologous GvHD, a term used to describe a similar phenomenon occurring after autologous HCT, has been a topic of controversy due to the obvious lack of genetic disparity between donor and recipient. Nonetheless, beyond the technical inaccuracy of the terminology, there might exist an under-diagnosed complication of autologous HCT that resembles GvHD occurring after allogeneic HCT.
Here we report an uncommon case of histologically proven, late recurrence of spontaneous gastrointestinal (GI) GvHD in a plasma cell myeloma (multiple myeloma (MM)) patient after autologous HCT. In this letter, we do not intend to debate the accuracy of the term 'autologous GvHD' and will use the term to refer to the observed clinical phenomenon described.
CASE DESCRIPTION
A 75-year-old G3P3 woman was diagnosed with Durie − Salmon stage IIIA IgA lambda plasma cell myeloma after presenting with back pain and recurrent bronchitis. She was treated with lenalidomide and dexamethasone for six cycles and attained a very good PR (VGPR). After mobilization with cyclophosphamide, progenitors were collected and she underwent autologous HCT after high-dose melphalan. Engraftment was achieved on posttransplant day 11. Her course was complicated by non-infectious diarrhea with an average of 10 watery bowel movements per day.
Lower endoscopy was performed 11 days after transplant and pathology showed colonic mucosa with epithelial damage, including cryptitis, apoptotic bodies, reactive and regenerative changes, which are histologic features consistent with GvHD ( Figure 1 ). There was no morphologic evidence of CMV. Clinical stage I grade II GI GvHD was diagnosed and therapy with prednisone 1 mg/kg per day and budesonide was initiated. Symptoms resolved and corticosteroids were tapered in 3 months.
Four years after transplant, disease progression was observed with an increase in serum IgA kappa to 3.3 g/dL and serum-free lambda light chains. She received six cycles of salvage therapy with weekly SC bortezomib and dexamethasone with a subsequent decrease in serum IgA lambda paraprotein to 0.5 g/dL. Nine months later, she progressed with increase in IgA lambda paraprotein to 3.4 g/dL and 60% marrow plasma cells. The patient was enrolled on a clinical trial and completed six cycles of lenalidomide 10 mg daily for 21 of 28 days each month, dexamethasone 40 mg weekly and SC 5-azacytidine 50 mg/m 2 given twice weekly. She attained VGPR and as per protocol received lenalidomide maintenance 10 mg by mouth daily for 21 of 28 days each month.
Six years after HCT and 10 months after initiation of the lenalidomide-containing regimen, she developed intermittent diarrhea and abdominal cramping, which worsened over the subsequent year to an average of five loose bowel movements per day. A colonoscopy was performed and pathology again showed findings consistent with histologic grade 1 − 2 GvHD ( Figure 2 ). Budesonide was initiated with immediate resolution of symptoms. On most recent follow-up, she had completed 24 cycles of lenalidomide with sustained VGPR. She continues on once daily budesonide with mild intermittent abdominal cramping and complete resolution of diarrhea.
Autologous GvHD refers to the clinical and histopathologic findings consistent with GvHD after autologous HCT or transplant from a genetically identical twin (syngeneic GvHD). Pathogenesis is attributed to the failure of self-tolerance occurring either spontaneously or in subjects receiving post-transplant immune modulation.
1,3-6 Based on preclinical animal models, there have Figure 1 . The colonic mucosa in autologous GvHD shows scattered crypts abscesses (a) (arrows; original magnification, × 200) and numerous apoptotic bodies with eosinophilic globules and nuclear debris (b) (arrow; original magnification, × 400).
been several trials designed to induce GvHD after autologous HCT with cyclosporine, interferon-γ or both in an attempt to enhance the host antitumor response. 3, [5] [6] [7] These studies propose that T-cell subset modification, particularly of the CD8+ T cells that erroneously recognize a self-peptide Ag presented by MHC class II molecule, leads to central impairment of immune tolerance favoring autoimmunity. [3] [4] [5] 7 Depletion of regulatory T cells by conditioning regimens and the presence of immune-competent self-reactive T cells post transplantation directed against recipient Ags are implicated in the pathophysiology of spontaneous autologous GvHD. 4 Another proposed mechanism for the development of syngeneic autologous GvHD is 'micro-chimerism', which refers to the persistence of fetal genetic material in parous female donors and may explain the higher incidence of autologous GvHD in genetically identical twin recipients and increased incidence of autologous GvHD in women. 4, 8 Hood et al. 1 reported an 8% incidence of grade 2 skin GvHD in 115 patients who received autologous and genetically identical twin HCT. Holmberg et al. 9 reported a 13% overall incidence of GI GvHD in 681 autologous HCT recipients. In this study, the diagnosis of GI GvHD was made based on symptoms (nausea, vomiting, anorexia, abdominal pain and diarrhea), endoscopy/ colonoscopy and histological evidence of apoptotic crypt epithelial cells with or without lymphocytic aggregates, or cypt cell dropout with focal lymphocytic infiltration. 9 While our patient developed diarrhea on day 7 after transplant and underwent endoscopy on day 11, the mean time to development of symptoms in their study was 15 days post transplant (range, 0-63 days) and the median time to histologically proven diagnosis was 42 days. 9 Our patient experienced isolated GI GvHD, while reported cases of autologous GvHD most commonly involve the skin. 1, 3, 9 The clinical, laboratory and histologic criteria used to diagnose acute GvHD lack specificity and this leads to diagnostic challenges. 10 For instance, infections, drug or radiation exposures can cause skin and GI epithelial changes that can mimic GvHD clinically and histologically at similar times after HCT. 10 In contrast to allogeneic GvHD, where the severity ranges from mild to severe, spontaneous autologous GvHD tends to be generally mild and steroid responsive. 9 However, Drobyski et al.
11
reported five cases of severe and steroid-refractory GvHD in patients receiving autologous HCT for MM. In this case series, patients were not preferentially treated with 'new' therapeutic agents (thalidomide, lenalidomide and bortezomib) relative to other MM patients in the cohort undergoing an autologous HCT. Three patients developed GvHD after a second autologous HCT and one patient developed GvHD while receiving thalidomide maintenance therapy after the first HCT. 11 Interestingly, none of the patients who underwent autologous HCT for acute myeloid leukemia or lymphoma developed severe GvHD. This raises the question as to whether mobilization with cyclophosphamide, conditioning with melphalan and/or the underlying myeloma triggered T-cell subset modification resulting in autoimmunity and the development of autologous GvHD. In a cohort of 40 identical twin transplants for aplastic anemia, Adams et al. 8 reported an association between the use of a conditioning regimen containing melphalan, busulfan and thiotepa and the subsequent development of acute GvHD. However, it is still unclear whether conditioning was a predisposing factor or a confounder with effects that mimicked GvHD. 10 Our patient developed clinical and histopathologic findings consistent with recurrent GvHD over 6 years after HCT and 10 months after the reintroduction of a lenalidomide-containing regimen. The timing of onset after initiation of lenalidomide is particularly notable given the known immunomodulatory effects of this agent. Galustian et al. 12 demonstrated that in vitro treatment with lenalidomide and pomalidomide (immunomodulatory drugs, IMiDs) has a direct inhibitory effect on regulatory T-cell proliferation and suppressor function secondary to decreased FOXP3 expression. 1 This can contribute to the derangement of self-tolerance and development of autoimmunity by depletion of regulatory T cells. Furthermore, Lazarus et al. 13 used flow cytometry to demonstrate that there is an enhanced expression of specific transcription regulators and surface receptors on CD34+ hematopoietic progenitor cells of patients who were previously treated with thalidomide, lenalidomide and bortezomib compared with controls who did not develop autologous GvHD after HCT for plasma cell myeloma. A retrospective study by Montefusco et al.
14 reported a 4.3% absolute increased risk of autoimmune disease occurrence in patients treated with lenalidomide for MM. In this study, thalidomide and lenalidomide were associated with an increased risk of developing autoimmune phenomena, preferentially in the first few months of treatment, and a previous autologous transplant was shown to be a significant risk factor. 14 Our case is the first report of a late recurrence of autologous GvHD in the context of lenalidomide use. Although this phenomenon remains to be fully understood, we hypothesize that immune dysregulation, secondary to exposure to pre-and post-HCT IMiDs and high-dose melphalan conditioning regimen, is the most convincing explanation of the observed late recurrence of 'graft-versus-host' or rather autoimmune attack on self-Ags and loss of self-tolerance. Despite the diagnostic challenge, and need to rule out other possible diagnoses for the observed clinical and histological findings, this case also highlights the importance of prompt recognition and treatment of autologous GvHD as an early or late complication after HCT especially in the era of rapidly evolving immunomodulatory agents that might lead to a higher
